European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10‐year experience
Open accessThe DOI matches its Crossref record.
Abstract
Background and purpose: Pompe disease is a rare inheritable muscle disorder for which enzyme replacement therapy (ERT) has been available since 2006. Uniform criteria for starting and stopping ERT in adult patients were developed and reported here. Methods: Three consensus meetings were organized through the European Pompe Consortium, a network of experts from 11 European countries in the field of Pompe disease. A systematic review of the literature was undertaken to determine the effectiveness of ERT in adult patients on a range of clinical outcome measures and quality of life. A narrative synthesis is presented. Results: Consensus was reached on how the diagnosis of Pompe disease should be confirmed, when treatment should be started, reasons for stopping treatment and the use of ERT during pregnancy. This was based on expert opinion and supported by the literature. One clinical trial and 43 observational studies, covering a total of 586 individual adult patients, provided evidence of a beneficial effect of ERT at group level. At individual patient level, the response to treatment varied, but factors associated with a patient's response to ERT were not described in many studies. Eleven observational studies focused on more severely affected patients, suggesting that ERT can also be beneficial in these patients. There are no studies on the effects of ERT in pre‐symptomatic patients. Conclusions: This is the first European consensus recommendation for starting and stopping ERT in adult patients with Pompe disease, based on the extensive experience of experts from different countries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Glycogen Storage Diseases: An Update
Gümüş, E., & Özen, H. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i25.3932 · Cited by 100
van der Meijden, J. C., Kruijshaar, M. E., Harlaar, L., Rizopoulos, D., van der Beek, N. A. M. E., & van der Ploeg, A. T. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-018-0166-3 · Cited by 37
“In adult patients, positive effects were also demonstrated on endurance, muscle strength, pulmonary function, and survival (Bembi et al 2010; Strothotte et al 2010; van der Ploeg et al 2010; Angelini et al 2012; de Vries et al 2012; Regnery et al 2012; van der Ploeg et al 2012; Anderson et al 2014; Stepien et al 2016;…”
BackgroundSelf-citation
Metadata
- Authors
- van der Ploeg, A. T., Kruijshaar, M. E., Toscano, A., Laforêt, P., Angelini, C., Lachmann, R. H., Pascual Pascual, S. I., Roberts, M., Rösler, K., Stulnig, T., van Doorn, P. A., Van den Bergh, P. Y. K., Vissing, J., Schoser, B., & the European Pompe Consortium
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2017-05-06
- Volume
- 24
- Issue
- 6
- Pages
- 768
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W2611287306
- Cited by
- 173
- References
- 0
- FWCI
- 11.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.